- Modular Medical (MODD, Financial) is set to present key findings at the American Diabetes Association's 85th Scientific Sessions in June 2025.
- The study investigates the effects of pump-delivery of GLP-1R agonist on diet-induced obese mice.
- The event will be held in Chicago, focusing on the comparison between exenatide pump delivery and intermittent semaglutide dosing.
Modular Medical, Inc. (MODD), a leader in insulin delivery technology, will present groundbreaking research at the American Diabetes Association's (ADA) 85th Scientific Sessions. The event will take place from June 20-23, 2025, at McCormick Place Convention Center in Chicago, Illinois. A poster presentation, numbered 783-P, is scheduled for June 22, 2025, between 12:30 PM and 1:30 PM.
The study focuses on the pump delivery of a GLP-1R agonist in diet-induced obese mice, comparing the continuous delivery of exenatide with the intermittent dosing of semaglutide. This research aims to address gastrointestinal tolerability challenges in GLP-1 therapy, which often lead to treatment discontinuation.
Modular Medical's innovative approach, showcased through its FDA-cleared patch pump designed for "almost-pumpers," suggests that personalized GLP-1 titration and dosing, including mealtime bolus options, could significantly improve treatment outcomes and patient tolerance. The company's participation in the ADA 85th Scientific Sessions aligns with its commitment to improving diabetes management through technological innovations.
